CrushSCI.com
105.1Average days
91Median days
31Fastest days
166Longest days
4322025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

31 days

Pharmacokinetic interactions of azithromycin and ethambutol with or without SPR720 in healthy participants

Authors
Shekman L. Wong; Xilla T. Ussery; Nivedita Bhatt; Kamal A. HamedShow moreShow less
Affiliations
1. Spero Therapeutics, Inc.Show moreShow less
Source PDF DOI Publisher page
161 days

Does pre-treatment with doxycycline improve the efficacy of combination minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium infections?

Authors
Kay Htaik; Lenka A. Vodstrcil; Erica L. Plummer; Laura G. Matthews; Ivette Aguirre; Fabian Y. S. Kong; Catriona S. BradshawShow moreShow less
Affiliations
1. Melbourne Sexual Health Centre, Alfred Health; 2. School of Translational Medicine, Monash University; 3. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of MelbourneShow moreShow less
Source PDF DOI Publisher page
140 days

DNA methyltransferase HP1208 antagonizes Fur-mediated repression of GlmU to modulate β-lactam susceptibility in Helicobacter pylori

Authors
Tongzhe Deng; Yanchao Wang; Yusong He; Hongyu Yan; Mengxin Liu; Feifei She; Yancheng WenShow moreShow less
Affiliations
1. Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, School of Basic Medical Sciences, Fujian Medical University; 2. Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical UniversityShow moreShow less
Source PDF DOI Publisher page
166 days

An open-label, Phase 1 study to evaluate the drug-drug interaction between ulonivirine and the combined oral contraceptive levonorgestrel/ethinyl estradiol in female participants without HIV with a validated liquid chromatograph

Authors
Makeda Robinson; Gillian Gillespie; Bhargava Kandala; Wendy Ankrom; Marian Iwamoto; Natasa Pajkovic; Yang Liu; Graigory C. Garrett; Martha Hernandez-Illas; Jesse C. NussbaumShow moreShow less
Affiliations
1. MRL, Merck & Co., Inc.; 2. Phase One Department, QPS Miami Research Associates, LLCShow moreShow less
Source PDF DOI Publisher page
82 days

In vitro and in vivo activity of OSUAB-0284, a preclinical candidate for Staphylococcus aureus infections

Authors
Chelsea A. Mann; Jason S. West; Sydney R. Cassel; Carter T. Wheat; Alexander D. Landgraf; Jake V. Tomkovicz; Xinyu Zhao; Sarah Eaton; Sheri Dellos-Nolan; Isaac Baldridge; Prakhar Srivastava; Angela Kennedy-Mendez; Christopher M. Pillar; David A. Hufnagel; Razieh Kebriaei; Charles E. Bell; Daniel J. Wozniak; Jack C. Yalowich; Mark J. Mitton-FryShow moreShow less
Affiliations
1. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University; 2. Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University; 3. Department of Biological Chemistry and Pharmacology, College of Medicine, The Ohio State University; 4. Ohio State Biochemistry Program, The Ohio State University; 5. Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University; 6. Microbiologics Antibiotic and Microbiome Research Center; 7. Department of Chemistry and Biochemistry, College of Arts and Sciences, The Ohio State University; 8. Department of Microbiology, College of Arts and Sciences, The Ohio State UniversityShow moreShow less
Source PDF DOI Publisher page
135 days

Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis

Authors
Abdullah Alshehri; Christopher L. King; Daryl J. MurryShow moreShow less
Affiliations
1. Department of Clinical Pharmacy, College of Pharmacy, King Khalid University; 2. Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University; 3. Veterans Affairs Research Service, VA Medical Center; 4. Department of Pharmacy Practice and Science, University of Nebraska Medical Center; 5. Fred and Pamela Buffett Cancer Center, University of Nebraska Medical CenterShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does ANTIMICROBIAL AGENTS AND CHEMOTHERAPY take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. The fastest paper went from submission to acceptance in 31 days (Pharmacokinetic interactions of azithromycin and ethambutol with or without SPR720 in healthy participants, received 2026-08-24, accepted 2026-09-24); the slowest took 166 days. The average is 105.1 days and the median is 91 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.